ITCI — Intra-Cellular Therapies Income Statement
0.000.00%
Last trade - 00:00- $7.64bn
- $7.14bn
- $464.37m
- 61
- 13
- 66
- 44
Annual income statement for Intra-Cellular Therapies, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.061 | 22.8 | 83.8 | 250 | 464 |
| Cost of Revenue | |||||
| Gross Profit | — | 20.9 | 75.8 | 230 | 431 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 154 | 254 | 369 | 514 | 624 |
| Operating Profit | -154 | -231 | -286 | -264 | -159 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -148 | -227 | -284 | -256 | -139 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -148 | -227 | -284 | -256 | -140 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -148 | -227 | -284 | -256 | -140 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -148 | -227 | -284 | -256 | -140 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.68 | -3.23 | -3.5 | -2.72 | -1.46 |